Protein A Resin Market, By Product (Natural Protein A and Recombinant Protein A), By Matrix Type (Agarose-based, Glass or Silica Based, and Organic Polymer Based), By Application (Immunoprecipitation and Antibody Purification), By End User (Biopharmaceutical Companies, Clinical Research Laboratories, and Academic Institutes), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Feb 2025

Code : CMI231

Pages :163

Formats :

Excel and PDF

Industry : Pharmaceutical

Protein A Resin Market Size and Trends

The Global Protein A Resin Market is estimated to be valued at USD 1.64 Bn in 2025 and is expected to reach USD 3.13 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.7% from 2025 to 2032.

Protein A Resin Market Key Factors

To learn more about this report, Request sample copy

The market is expected to witness positive growth over the forecast period. Growing biopharmaceutical industry and increasing research and development activities in pharma and biotech companies are expected to drive the demand for protein A resins. Additionally, the increasing production of monoclonal antibodies for therapeutic applications will also contribute to the growth of the protein A resin market. Furthermore, the growing prevalence of chronic diseases globally is increasing the demand for biologic drugs, which, in turn, is propelling the market growth. However, availability of alternative affinity chromatography resins may hinder the market growth of protein A resin to a certain extent during the forecast period.

Increasing focus on developing biologics such as monoclonal antibodies (mAbs) for therapeutic purposes

The demand for monoclonal antibody therapies is increasing rapidly owing to their high specificity and ability to treat various chronic and life-threatening diseases. Protein A resin plays a critical role in the downstream purification process of monoclonal antibodies during their production. As the development and approval of novel monoclonal antibodies continue to grow for indications like cancer, autoimmune disorders, and infectious diseases, the requirement for protein A resin is expected to rise substantially. Major pharmaceutical companies are making heavy investments in developing highly innovative monoclonal antibody drugs and bringing them into the market. This massive pipeline of monoclonal antibodies in clinical trials and extensive research on complex antibody therapeutics will drive the need for large volumes of protein A resins over the coming years. For instance, in March 2025, ClinicalTrial.gov reported 1,248 ongoing clinical studies focused on monoclonal antibodies in the U.S. This significant number underscores a robust biopharmaceutical development pipeline centered around monoclonal antibodies. Consequently, the increasing demand for protein A resins is closely aligned with scaling purification and production processes, thereby driving the market growth in this sector.